CRYSTAL KAPLAN: Open Payments
NPI 1124584206 · ASHEVILLE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$487 in 23 payments from 15 companies in 2025. Trend: 2023 $722 · 2024 $677 · 2025 $487
Food & beverage: $487
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 4 | $78 |
| Celgene Corporation | 3 | $61 |
| Daiichi Sankyo Inc. | 2 | $51 |
| AstraZeneca Pharmaceuticals LP | 2 | $46 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
| Merck Sharp & Dohme LLC | 1 | $28 |
| Eisai Inc. | 1 | $28 |
| GlaxoSmithKline, LLC. | 1 | $26 |
| Genentech USA, Inc. | 1 | $23 |
| ARRAY BIOPHARMA INC | 1 | $22 |
Products named: ENHERTU, Trodelvy, REBLOZYL, KEYTRUDA, Lenvima, JEMPERLI, Itovebi, LORBRENA.
Industry payments across NC — which companies pay providers there.
